Biotech Bay
Filter News
Found 80,392 articles
-
As BioSpace proudly introduces our 2022 Hotbed Maps, let’s explore the industry’s most thriving territories, research leading employers and search for relevant jobs on BioSpace. -
AceLink Therapeutics Appoints Pedro Huertas, M.D., Ph.D., as Chief Medical Officer
5/8/2023
AceLink Therapeutics, Inc. today announced the appointment of Pedro Huertas, M.D., Ph.D., as Chief Medical Officer (CMO).
-
FibroGen Enters into Exclusive License for FOR46 with Fortis Therapeutics
5/8/2023
FibroGen, Inc. (Nasdaq: FGEN) and Fortis Therapeutics announced that FibroGen has entered into an exclusive license with Fortis Therapeutics for FOR46, a potential first-in-class Phase 1 antibody-drug conjugate (ADC) targeting a novel epitope on CD46.
-
Innovent Updates the Results from the ORIENT-31 Study of Sintilimab Plus Chemotherapy With or Without Bevacizumab in Patients with EGFR-TKI failed EGFR-mutated Non-Squamous Non-Small Cell Lung Cancer in the Lancet Respiratory Medicine
5/8/2023
Innovent Biologics, Inc. announces that second interim analysis and survival analysis results of the ORIENT-31 study have been published in the Lancet Respiratory Medicine.
-
Innovent Announces First Participant Dosed in Phase 3 Study (RESTORE) of IBI311 (Anti-IGF-1R Monoclonal Antibody) in Patients with Thyroid Eye Disease
5/8/2023
Innovent Biologics, Inc. announces that the first patient with Thyroid Eye Disease has been successfully dosed in the Phase 3 study of IBI311, a recombinant anti-insulin-like growth factor-1 receptor monoclonal antibody.
-
NEW DATA FROM AMGEN'S PROLIA® (DENOSUMAB) DEMONSTRATES SIGNIFICANT REDUCTION IN OSTEOPOROTIC FRACTURE RISK COMPARED TO ALENDRONATE
5/8/2023
Amgen (NASDAQ:AMGN) today announced new data from a real-world study of nearly half of a million postmenopausal women with osteoporosis in the U.S. medicare program showing Prolia® (denosumab) injection reduced fracture risk in patients versus oral alendronate, a frequently prescribed bisphosphonate treatment.
-
Hummingbird Bioscience to Present Preclinical Proof of Concept for Potentially First-In-Class Antibody Targeting Autoimmune Diseases
5/8/2023
Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, announced an upcoming poster presentation at IMMUNOLOGY2023™.
-
Jaguar Health to Hold Investor Webcast Monday, May 15th at 8:30 AM EDT Regarding Q1 2023 Financials & Corporate Updates
5/8/2023
Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company will conduct an investor webcast on Monday, May 15, 2023 at 8:30 a.m. Eastern Daylight Time to review first-quarter 2023 financials and provide corporate updates.
-
Benitec Biopharma to Present at the JMP Securities Life Sciences Conference
5/8/2023
Benitec Biopharma Inc. today announced that Jerel A. Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer of Benitec will present at the JMP Securities Life Sciences Conference on Tuesday, May 16th, 2023 at 2:00 pm.
-
AltruBio Announces Poster Presentation at Digestive Disease Week Conference 2023
5/8/2023
AltruBio Inc. today announced that David T. Rubin, M.D., Professor of Medicine and Pathology at the University of Chicago and AltruBio Scientific Advisory Board member, will share a poster presentation on immune checkpoint enhancer (ICE), ALTB-168, during Digestive Disease Week®, taking place at McCormick Place in Chicago, IL, from May 6-9, 2023.
-
Bio-Rad to Participate in Fireside Chat During 2023 RBC Capital Markets Global Healthcare Conference
5/8/2023
Bio-Rad Laboratories, Inc. today announced that the company’s management will participate in a fireside chat event during the 2023 RBC Capital Markets Global Healthcare Conference on Wednesday, May 17, 2023, at 3:35 PM Eastern Time (12:35 PM Pacific Time).
-
Olema Oncology Announces Upcoming Poster Presentation at the 2023 ESMO Breast Cancer Annual Congress
5/8/2023
Olema Pharmaceuticals, Inc. today announced a poster presentation on OP-1250, the Company’s complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD) in development for the treatment of metastatic breast cancer, at the upcoming ESMO Breast Cancer Annual Congress 2023 taking place May 11-13, 2023, in Berlin, Germany.
-
CareDx to Report First Quarter 2023 Financial Results
5/8/2023
CareDx, Inc. today announced it will report financial results for the first quarter 2023 after market close on Wednesday, May 10, 2023.
-
Vaxcyte Reports First Quarter 2023 Financial Results and Provides Business Update
5/8/2023
Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced financial results for the first quarter ended March 31, 2023 and provided a business update.
-
ORIC Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Updates
5/8/2023
ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today reported financial results and operational updates for the quarter ended March 31, 2023.
-
FibroGen Reports First Quarter 2023 Financial Results
5/8/2023
FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the first quarter 2023 and provided an update on the company’s recent developments.
-
Denali Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
5/8/2023
Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the first quarter ended March 31, 2023, and provided business highlights.
-
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2023 Financial Results
5/8/2023
Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the quarter ended March 31, 2023.
-
Shockwave Medical Reports First Quarter 2023 Financial Results
5/8/2023
Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months ended March 31, 2023.
-
Revolution Medicines Reports First Quarter 2023 Financial Results and Update on Corporate Progress
5/8/2023
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced its financial results for the quarter ended March 31, 2023, and provided an update on corporate progress.